anky1212
Junior

India,
2019-02-21 05:05

Posting: # 19951
Views: 211
 

 Health Canada Study reports [Regulatives / Guidelines]

Dear All,

As per Health canada guidance document, "To avoid study bias, comparative bioavailability studies should be conducted in such a way that the subjects are not aware of which product (test or reference) is being administered. Furthermore, the persons checking for adverse reactions and those conducting the bioanalysis of samples should not know the treatment sequence."

In this case, if adverse events is ongoing, analysis both analytical and statistical phase completed, shall we submit treatment or code in study report?

Upto which phase guidance is applicable?

After completion of statistical phase if adverse event is still ongoing, still we need to follow guidance?

Thanks
Ankur Patel
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
19,289 posts in 4,100 threads, 1,316 registered users;
online 21 (2 registered, 19 guests [including 6 identified bots]).

A refund for defective software might be nice,
except it would bankrupt the entire software industry
in the first year.    Andrew S. Tanenbaum

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5